본문 바로가기
KERD
논문KCI 등재

Single-center study on clinicopathological and typical molecular pathologic features of metastatic brain tumor

이영숙|이연수|박재성|이성학|강준|전신수|이아원|이수화|성연은
대한병리학회|2023.07|Journal of Pathology and Translational Medicine|제57권 제4호|pp. 217-231

0

조회

0

다운로드

0

인용

0

참고문헌

키워드

Clinical pathologyMolecular pathologyBrain metastases
주제분류병리학

초록

Background: The metastatic brain tumor is the most common brain tumor. The aim of this study was to demonstrate the clinicopathological and molecular pathologic features of brain metastases (BM). Methods: A total of 269 patients were diagnosed with BM through surgical resection at Seoul St. Mary’s Hospital from January 2010 to March 2020. We reviewed the clinicopathological features and molecular status of primary and metastatic brain tissues using immunohistochemistry and molecular pathology results. Results: Among 269 patients, 139 males and 130 females were included. The median age of primary tumor was 58 years (range, 13 to 87 years) and 86 patients (32.0%) had BM at initial presentation. Median BM free interval was 28.0 months (range, 1 to 286 months). The most frequent primary site was lung 46.5% (125/269), and followed by breast 15.6% (42/269), colorectum 10.0% (27/269). Epidermal growth factor receptor (EGFR) mutation was found in 50.8% (32/63) and 58.0% (40/69) of lung primary and BM, respectively. In both breast primary and breast cancer with BM, luminal B was the most frequent subtype at 37.9% (11/29) and 42.9% (18/42), respectively, followed by human epidermal growth factor receptor 2 with 31.0% (9/29) and 33.3% (14/42). Triple-negative was 20.7% (6/29) and 16.7% (7/42), and luminal A was 10.3% (3/29) and 7.1% (3/42) of breast primary and BM, respectively. In colorectal primary and colorectal cancer with BM, KRAS mutation was found in 76.9% (10/13) and 66.7% (2/3), respectively. Conclusions: We report the clinicopathological and molecular pathologic features of BM that can provide useful information for understanding the pathogenesis of metastasis and for clinical trials based on the tumor’s molecular pathology.

Abstract

Background: The metastatic brain tumor is the most common brain tumor. The aim of this study was to demonstrate the clinicopathological and molecular pathologic features of brain metastases (BM). Methods: A total of 269 patients were diagnosed with BM through surgical resection at Seoul St. Mary’s Hospital from January 2010 to March 2020. We reviewed the clinicopathological features and molecular status of primary and metastatic brain tissues using immunohistochemistry and molecular pathology results. Results: Among 269 patients, 139 males and 130 females were included. The median age of primary tumor was 58 years (range, 13 to 87 years) and 86 patients (32.0%) had BM at initial presentation. Median BM free interval was 28.0 months (range, 1 to 286 months). The most frequent primary site was lung 46.5% (125/269), and followed by breast 15.6% (42/269), colorectum 10.0% (27/269). Epidermal growth factor receptor (EGFR) mutation was found in 50.8% (32/63) and 58.0% (40/69) of lung primary and BM, respectively. In both breast primary and breast cancer with BM, luminal B was the most frequent subtype at 37.9% (11/29) and 42.9% (18/42), respectively, followed by human epidermal growth factor receptor 2 with 31.0% (9/29) and 33.3% (14/42). Triple-negative was 20.7% (6/29) and 16.7% (7/42), and luminal A was 10.3% (3/29) and 7.1% (3/42) of breast primary and BM, respectively. In colorectal primary and colorectal cancer with BM, KRAS mutation was found in 76.9% (10/13) and 66.7% (2/3), respectively. Conclusions: We report the clinicopathological and molecular pathologic features of BM that can provide useful information for understanding the pathogenesis of metastasis and for clinical trials based on the tumor’s molecular pathology.

참고문헌 (69)

  1. Sacks P, "Epidemiology of brain metastases", Neurosurg Clin N Am, 31, pp.481~488 (2020)
  2. Barnholtz-Sloan JS, "Incidence proportions of brain metastases in patients diagnosed(1973 to 2001)in the Metropolitan Detroit Cancer Surveillance System", J Clin Oncol, 22, pp.2865~2872 (2004)
  3. Counsell CE, "Incidence of intracranial tumours in the Lothian region of Scotland, 1989-90", J Neurol Neurosurg Psychiatry, 61, pp.143~150 (1996)
  4. Jung J, "Discordances in ER, PR, and HER2between primary breast cancer and brain metastasis", J Neurooncol, 137, pp.295~302 (2018)
  5. Sundaresan N, "Surgical treatment of brain metastases : clinical and computerized tomography evaluation of the results of treatment", Cancer, 55, pp.1382~1388 (1985)
  6. Schackert G, "Surgical management of single and multiple brain metastases : results of a retrospective study", Onkologie, 24, pp.246~255 (2001)
  7. Nahed BV, "Congress of neurological surgeons systematic review and evidence-based guidelines on the role of surgery in the management of adults with metastatic brain tumors", Neurosurgery, 84, pp.E152~E155 (2019)
  8. Allred DC, "Prognostic and predictive factors in breast cancer by immunohistochemical analysis", Mod Pathol, 11, pp.155~168 (1998)
  9. Wolff AC, "Human epidermal growth factor receptor 2 testing in breast cancer : American Society of Clinical Oncology", College of American Pathologists clinical practice guideline focused update, 2018, pp.36, 2105~2122
  10. Wolff AC, "Recommendations for human epidermal growth factor receptor 2 testing in breast cancer : American Society of Clinical Oncology", College of American Pathologists clinical practice guideline update, 2013, pp.31, 3997~4013
  11. Dowsett M, "Assessment of Ki67 in breast cancer : recommendations from the International Ki67 in Breast Cancer working group", J Natl Cancer Inst, 103, pp.1656~1664 (2011)
  12. Goldhirsch A, "Personalizing the treatment of women with early breast cancer : highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013", Ann Oncol, 24, pp.2206~2223 (2013)
  13. 정예슬, "Analysis of the molecular subtypes of preoperative core needle biopsy and surgical specimens in invasive breast cancer", Journal of Pathology and Translational Medicine, 54(1), pp.87~94 (2020), 대한병리학회[DOI]
  14. Berghoff AS, "Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers", ESMO Open, 1, pp.e000024~ (2016)[DOI]
  15. Stark AM, "Surgical treatment for brain metastases : prognostic factors and survival in 309 patients with regard to patient age", J Clin Neurosci, 18, pp.34~38 (2011)
  16. Sperduto PW, "Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases : a multi-institutional analysis of 4, 259patients", Int J Radiat Oncol Biol Phys, 77, pp.655~661 (2010)
  17. Christensen TD, "Systematic review : brain metastases from colorectal cancer : incidence and patient characteristics", BMC Cancer, 16, pp.260~ (2016)
  18. Siegel RL, "Cancer statistics, 2022", CA Cancer J Clin, 72, pp.7~33 (2022)
  19. Dyba T, "The European cancer burden in 2020 : incidence and mortality estimates for 40 countries and 25 major cancers", Eur J Cancer, 157, pp.308~347 (2021)
  20. 강미주, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2019", Cancer Research and Treatment, 54(2), pp.330~344 (2022), 대한암학회[DOI]
  21. Che W, "Recent trends in synchronous brain metastasis incidence and mortality in the United States : tenyear multicenter experience", Curr Oncol, 29, pp.8374~8389 (2022)
  22. Hubbs JL, "Factors associated with the development of brain metastases : analysis of 975 patients with early stage nonsmall cell lung cancer", Cancer, 116, pp.5038~5046 (2010)
  23. Sun MS, "Brain metastasis in de novo breast cancer : an updated population-level study from SEER database", Asian J Surg, 45, pp.2259~2267 (2022)
  24. Yang L, "Brain metastases in newly diagnosed colorectal cancer : a population-based study", Cancer Manag Res, 10, pp.5649~5658 (2018)
  25. Zhang YL, "The prevalence of EGFR mutation in patients with non-small cell lung cancer : a systematic review and meta-analysis", Oncotarget, 7, pp.78985~78993 (2016)
  26. Villalva C, "EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77NSCLC patients", Cancer Med, 2, pp.296~304 (2013)
  27. Nicos M, "Screening for gene mutations in central nervous system metastases of non-small-cell lung cancer", Brain Pathol, 28, pp.295~297 (2018)
  28. Luo D, "EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases", Tumour Biol, 35, pp.2437~2444 (2014)
  29. Rau KM, "Discordance of mutation statuses of epidermal growth factor receptor and K-ras between primary adenocarcinoma of lung and brain metastasis", Int J Mol Sci, 17, pp.524~ (2016)
  30. Kyung-Min Kim, "Discordance of Epidermal Growth Factor Receptor Mutation between Brain Metastasis and Primary Non-Small Cell Lung Cancer", Brain Tumor Research and Treatment, 7(2), pp.137~140 (2019), 대한뇌종양학회[DOI]
  31. Gow CH, "Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-smallcell lung cancer", Ann Oncol, 20, pp.696~702 (2009)
  32. Cheng X, "Tumor heterogeneity and resistance to EGFRtargeted therapy in advanced nonsmall cell lung cancer : challenges and perspectives", Onco Targets Ther, 7, pp.1689~1704 (2014)
  33. Marusyk A, "Tumor heterogeneity : causes and consequences", Biochim Biophys Acta, 1805, pp.105~117 (2010)
  34. Rosell R, "Screening for epidermal growth factor receptor mutations in lung cancer", N Engl J Med, 361, pp.958~967 (2009)
  35. Yu HA, "Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers", Clin Cancer Res, 19, pp.2240~2247 (2013)
  36. Sequist LV, "Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors", Sci Transl Med, 3, pp.75ra26~ (2011)[DOI]
  37. Koivunen JP, "EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer", Clin Cancer Res, 14, pp.4275~4283 (2008)
  38. Wong DW, "The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS", Cancer, 115, pp.1723~1733 (2009)
  39. Perner S, "EML4-ALK fusion lung cancer : a rare acquired event", Neoplasia, 10, pp.298~302 (2008)
  40. Fallet V, "Prospective screening for ALK : clinical features and outcome according to ALK status", Eur J Cancer, 50, pp.1239~1246 (2014)
  41. Rangachari D, "Brain metastases in patients with EGFR-mutated or ALK-rearranged non-smallcell lung cancers", Lung Cancer, 88, pp.108~111 (2015)
  42. Costa DB, "CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib", J Clin Oncol, 29, pp.e443~e445 (2011)
  43. Barlesi F, "Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC)", Ann Oncol, 27(Suppl 6), pp.VI437~ (2016)
  44. Kim DW, "Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-smallcell lung cancer : a randomized, multicenter phase II trial", J Clin Oncol, 35, pp.2490~2498 (2017)
  45. Cancer Genome Atlas Research Network, "Comprehensive molecular profiling of lung adenocarcinoma", Nature, 511, pp.543~550 (2014)
  46. Imielinski M, "Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing", Cell, 150, pp.1107~1120 (2012)
  47. Kalikaki A, "Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC", Br J Cancer, 99, pp.923~929 (2008)
  48. Timar J, "Molecular epidemiology and diagnostics of KRAS mutations in human cancer", Cancer Metastasis Rev, 39, pp.1029~1038 (2020)
  49. Vassella E, "Mutational profiles of primary pulmonary adenocarcinoma and paired brain metastases disclose the importance of KRAS mutations", Eur J Cancer, 159, pp.227~236 (2021)
  50. Yonemori K, "Immunohistochemical profiles of brain metastases from breast cancer", J Neurooncol, 90, pp.223~228 (2008)
  51. Hoefnagel LD, "Receptor conversion in distant breast cancer metastases", Breast Cancer Res, 12, pp.R75~ (2010)
  52. Omoto Y, "Immunohistochemical assessment of primary breast tumors and metachronous brain metastases, with particular regard to differences in the expression of biological markers and prognosis", Exp Ther Med, 1, pp.561~567 (2010)
  53. Brogi E, "Breast carcinoma with brain metastases : clinical analysis and immunoprofile on tissue microarrays", Ann Oncol, 22, pp.2597~2603 (2011)
  54. Duchnowska R, "Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain", Breast Cancer Res, 14, pp.R119~ (2012)
  55. Shen Q, "Breast cancer with brain metastases : clinicopathologic features, survival, and paired biomarker analysis", Oncologist, 20, pp.466~473 (2015)
  56. Thomson AH, "Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes", Br J Cancer, 114, pp.793~800 (2016)
  57. Jiaxin C, "Conversion of ER, PR, HER2and Ki-67 and prognosis in breast cancer metastases to the brain", Front Neurol, 13, pp.1002173~ (2022)
  58. Hulsbergen AFC, "Subtype switching in breast cancer brain metastases : a multicenter analysis", Neuro Oncol, 22, pp.1173~1181 (2020)
  59. Turner KM, "Heterogeneity within molecular subtypes of breast cancer", Am J Physiol Cell Physiol, 321, pp.C343~C354 (2021)
  60. Yildiz-Aktas IZ, "The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma", Mod Pathol, 25, pp.1098~1105 (2012)
  61. Allison KH, "Estrogen and progesterone receptor testing in breast cancer : ASCO", CAP guideline update, 2020, pp.38, 1346~1366
  62. Van Poznak C, "Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer : American Society of Clinical Oncology clinical practice guideline", J Oncol Pract, 11, pp.514~516 (2015)
  63. Prior IA, "A comprehensive survey of Ras mutations in cancer", Cancer Res, 72, pp.2457~2467 (2012)
  64. Roussille P, "Pathological and molecular characteristics of colorectal cancer with brain metastases", Cancers (Basel), 10, pp.504~ (2018)
  65. Bozyk A, "Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer", Arch Med Sci, 18, pp.1221~1230 (2022)
  66. 이성학, "KRAS Mutation Test in Korean Patients with Colorectal Carcinomas: A Methodological Comparison between Sanger Sequencing and a Real-Time PCR-Based Assay", Journal of Pathology and Translational Medicine, 51(1), pp.24~31 (2017), 대한병리학회[DOI]
  67. Yaeger R, "RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer", Cancer, 121, pp.1195~1203 (2015)
  68. Li Y, "Analysis of KRAS, NRAS, and BRAF mutations, microsatellite instability, and relevant prognosis effects in patients with early colorectal cancer : a cohort study in East Asia", Front Oncol, 12, pp.897548~ (2022)
  69. Behel V, "Impact of molecular tumor board on the clinical management of patients with cancer", JCO Glob Oncol, 8, pp.e2200030~ (2022)

관련 논문AI추천

Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with nonsmall cell lung cancerDong Bok Shin, Eun Kyung Cho, Hee Kyung Ahn, Hwa-Sun Park, Inkeun Park, Jae Hoon Lee, Jinny Park, Junshik Hong, Kyu Ree Park, Min Young Baek, Shin Myung Kang, Sun Jin Sym, Young Saing Kim대한내과학회 · The Korean Journal of Internal Medicine2018 · 제33권 제1호Epidemiology of Intracranial Metastases in Korea: A National Cohort Investigation김세현, 김유정, 김인아, 김재용, 김지현, 김택균, 송창훈, 한정호대한암학회 · Cancer Research and Treatment2018 · 제50권 제1호The Pattern of Care for Brain Metastasis from Breast Cancer over the Past 10 Years in Korea: A Multicenter Retrospective Study (KROG 16-12)강기문, 권진이, 김경수, 김규보, 김대용, 김수지, 김용배, 김인아, 김재식, 김지현, 김진희, 김태현, 김희준, 남지호, 박연희, 신경환, 오윤경, 윤원섭, 이시원, 임석아, 장지석, 정웅기, 정원근, 차지혜, 최두호, 최병옥대한암학회 · Cancer Research and Treatment2022 · 제54권 제4호Surgical Outcomes of Hemorrhagic Metastatic Brain Tumors유헌, 곽호신, 신상훈, 이승훈, 정유진대한암학회 · Cancer Research and Treatment2011 · 제43권 제2호The efficacy of EGFR-tyrosine kinase inhibitor in non-small cell lung cancer patients with synchronous brain metastasis: a real-world study최진혁, Geum Sook Jeong, Hyun Woo Lee, Mi Sun Ahn, O kyu Noh, Se-Hyuk Kim, Seok Yun Kang, Seung Soo Sheen, Tae Hoon Roh, Yong Won Choi, Young-Taek Oh대한내과학회 · The Korean Journal of Internal Medicine2022 · 제37권 제2호Adjunctive markers for classification and diagnosis of central nervous system tumors: results of a multi-center neuropathological survey in Korea김나래, 김세훈, 차윤진대한병리학회 · Journal of Pathology and Translational Medicine2020 · 제54권 제2호

이 간행물의 다른 논문 (7건)

A review of liver fibrosis and cirrhosis regressionMichael J. Leepp. 189-195A stepwise approach to fine needle aspiration cytology of lymph nodes차희정, 김현정, Jamshid Abdul-Ghafar, 정요셉, 이승숙, 강창석, 박경신pp. 196-207Reevaluating diagnostic categories and associated malignancy risks in thyroid core needle biopsy정찬권pp. 208-216Loss of aquaporin-1 expression is associated with worse clinical outcomes in clear cell renal cell carcinoma: an immunohistochemical study김보현, 이석현, 문경철, 정민선pp. 232-237Metastatic choroidal melanoma in the breast: a case report and review of the literatureLoay Abudalu, Sami Titi, Nabila Nasir, Vinisha Malhotrapp. 238-241
원문 보기